Analysts have been eager to weigh in on the Healthcare sector with new ratings on Concert Pharma (CNCE – Research Report) and Arcutis Biotherapeutics (ARQT – Research Report).
Concert Pharma (CNCE)
Concert Pharma received a Hold rating from JonesTrading analyst Sean Kim PhD today. The company’s shares closed last Friday at $8.28, close to its 52-week high of $8.33.
According to TipRanks.com, PhD is a 3-star analyst with an average return of
Concert Pharma has an analyst consensus of Hold, with a price target consensus of $11.67, representing a 40.8% upside. In a report released yesterday, JMP Securities also downgraded the stock to Hold.
See Insiders’ Hot Stocks on TipRanks >>
Arcutis Biotherapeutics (ARQT)
In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Arcutis Biotherapeutics, with a price target of $61.00. The company’s shares closed last Friday at $15.71.
According to TipRanks.com, Ear is a 4-star analyst with an average return of
Arcutis Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $52.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CNCE:
